secwatch.observer — SEC 8-K summary
======================================

Issuer:     LIGAND PHARMACEUTICALS INC (LGND)
CIK:        0000886163
Form:       8-K
Filed at:   2024-01-08T23:59:59+00:00
Accession:  0000886163-24-000002
Event type: regulatory
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA approves Ligand's ZELSUVMI for molluscum contagiosum in adults and children 1+
--------------------------------------------------------------------------------

- FDA approved ZELSUVMI (berdazimer topical gel, 10.3%) for molluscum contagiosum in patients 1 year and older.
- First novel drug for molluscum and first topical prescription that can be applied at home.
- Approximately 6 million Americans infected annually; up to 73% of children go untreated.
- Product expected to be available in the U.S. in the second half of 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/886163/000088616324000002/0000886163-24-000002-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/886163/000088616324000002/lgnd-20240105.htm
  HTML page:      https://secwatch.observer/filing/0000886163-24-000002

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer